2023-507850-33-00已完成3 期
A Phase 3, Open-label, Single Arm, Multicenter Study of Ravulizumab in Addition to Best Supportive Care in Pediatric Participants (from 1 month to <18 years of age) with Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplantation (HSCT)
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 14
- 试验地点
- 23
- 主要终点
- TMA response
研究概览
简要总结
To assess the efficacy of ravulizumab plus BSC in the treatment of pediatric participants with HSCT-TMA
入排标准
- 年龄范围
- 0 years 至 17 years（0-17 Years）
- 接受健康志愿者
- 是
入选标准
- •≥ 28 days of age up to < 18 years of age at the time of signing the informed consent
- •Participants who received HSCT within the past 12 months at the time of Screening
- •A TMA diagnosis, based on meeting all of the following criteria during the Screening Period and/or ≤ 14 days prior to the Screening Period : • De novo thrombocytopenia or platelet transfusion refractoriness • Any one of the following markers of hemolysis: −Lactate dehydrogenase > ULN for age, − Presence of schistocytes ≥ 2 high power field (HPF) or ≥ 1% in peripheral blood smear • Proteinuria on spot urinalysis • De novo anemia OR Presence of hypertension
- •Participants must have HSCT-TMA that persists for at least 72 hours after initial management of any triggering agent/condition
- •Body weight ≥ 5 kg at Screening or ≤7 days prior to the start of the Screening Period (date of consent)
- •Male or female contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
- •Vaccinated against meningococcal infections if clinically feasible, according to national guidelines and recommendationsfor immune reconstitution after HSCT. Participants must be re-vaccinated against Haemophilus influenzae type b (Hib) and Streptococcus pneumoniae if clinically feasible, according to institutional guidelines for immune reconstitution after HSCT. All participants should be administered coverage with prophylactic antibiotics according to institutional posttransplant infection prophylaxis guidances including coverage against N. meningitidis for at least 2 weeks after meningococcal vaccination. Participants who cannot receive meningococcal vaccine should receive antibiotic prophylaxis guidance including coverage against N. meningitidis the entire Treatment Period and for 8 months following the final dose of ravulizumab.
- •Participants or their legally authorized representative must be capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent or assent form and in this protocol
排除标准
- •Known familial or acquired 'a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13' (ADAMTS13) deficiency (activity < 5%)
- •Pregnancy or breastfeeding
- •Hypersensitivity to murine proteins or to 1 of the excipients of ravulizumab
- •Previously or currently treated with a complement inhibitor
- •Known Shiga toxin-related hemolytic uremic syndrome (ST-HUS)
- •Positive direct Coombs test
- •Clinical diagnosis or suspicion of disseminated intravascular coagulation (DIC)
- •Known bone marrow/graft failure for the current HSCT
- •Diagnosis of veno-occlusive disease (VOD)
- •Human immunodeficiency virus (HIV) infection evidenced by HIV-1 or HIV-2 antibody titer
- •Unresolved meningococcal disease
- •Presence of sepsis requiring vasopressor support within 7 days prior to enrollment
结局指标
主要结局
TMA response
TMA response
次要结局
- Time to TMA response
- Change from baseline in TMA-associated organ dysfunction in renal system, cardiovascular system, pulmonary system, CNS, and GI system at 6 months and 1 year
- TMA relapse during the follow-up period
- Overall survival
- Non-relapse mortality
- Platelet response
- Hematologic response
研究者
European Clinical Trial Information
Scientific
Alexion Pharmaceuticals Inc.
研究点 (23)
Loading locations...
相似试验
已完成
3 期
A Phase 3, Open-Label, Single-arm, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Activity, and Safety of Ravulizumab Administered Subcutaneously in Pediatric Participants (2 to < 18 years of age) with Paroxysmal Nocturnal Hemoglobinuria (PNH) or Atypical Hemolytic Uremic Syndrome (aHUS)2022-502335-19-00Alexion Pharmaceuticals Inc.14
招募中
2 期
A multicentre trial evaluating the combination of a MEK inhibitor and a
PDL1 inhibitor in pediatric and adult patients with locally advanced and/or
metastatic soft tissue sarcoma2024-510712-75-00Centre Leon Berard80
招募中
3 期
A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adolescents (6 to < 18 Years Old) With Moderate Atopic DermatitisAtopic Dermatitis2024-518156-24-00Incyte Corp.150
招募中
3 期
Study of durvalumab or placebo administered with radiation therapy for patients with early stage non-small cell lung cancer
Study of osimertinib administered after radiation therapy in patients with early stage non-small cell lung cancer harboring an EGFR mutation2024-512667-31-00AstraZeneca AB148
招募中
3 期
A study to learn if rozanolixizumab is safe, how it moves through the body, and if it works in children with myasthenia gravisGeneralized Myasthenia Gravis2022-502074-16-00UCB Biopharma7